Turn Therapeutics Inc. (TTRX) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - |
| Cost of Goods Sold | 14.45K | 14.15K | 13.68K | 0 |
| COGS % of Revenue | - | - | - | - |
| Gross Profit | -14.45K | -14.15K | -13.68K | 0 |
| Gross Margin % | - | - | - | - |
| Gross Profit Growth % | - | - | - | - |
| Operating Expenses | 1.23M | 2.18M | 1.9M | 1.37M |
| OpEx % of Revenue | - | - | - | - |
| Selling, General & Admin | 1.12M | 2.14M | 1.74M | 1.3M |
| SG&A % of Revenue | - | - | - | - |
| Research & Development | 109.43K | 34.93K | 158.7K | 62.68K |
| R&D % of Revenue | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 |
| Operating Income | -1.25M | -2.19M | -1.91M | -1.37M |
| Operating Margin % | - | - | - | - |
| Operating Income Growth % | - | - | - | - |
| EBITDA | -1.23M | -2.18M | -1.9M | -1.37M |
| EBITDA Margin % | - | - | - | - |
| EBITDA Growth % | - | - | - | - |
| D&A (Non-Cash Add-back) | 14.45K | 14.15K | 13.68K | 0 |
| EBIT | -1.25M | -2.19M | -1.91M | -1.37M |
| Net Interest Income | 49.68K | 14.18K | 5.11K | 5.13K |
| Interest Income | 49.68K | 14.18K | 5.11K | 5.13K |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income/Expense | 275.17K | 2.47M | 9.37K | 126.11K |
| Pretax Income | -970.97K | 279.07K | -1.9M | -1.24M |
| Pretax Margin % | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% |
| Net Income | -970.97K | 279.07K | -1.9M | -1.24M |
| Net Margin % | - | - | - | - |
| Net Income Growth % | - | - | - | - |
| Net Income (Continuing) | -970.97K | 279.07K | -1.9M | -1.24M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.03 | 0.01 | -0.07 | -0.09 |
| EPS Growth % | - | - | - | - |
| EPS (Basic) | -0.03 | 0.01 | -0.07 | -0.09 |
| Diluted Shares Outstanding | 29.48M | 29.45M | 28.02M | 13.74M |
| Basic Shares Outstanding | 29.48M | 29.45M | 28.02M | 13.74M |
| Dividend Payout Ratio | - | - | - | - |